Notably, the potential role of USP44 as a regulator of the anti‐tumor immune response was not explored in any of these studies, and, indeed, the ability of this and other DUBs to control FOXP3 expression and Treg function in cancer has yet to be explored in detail. This evidence concerns the gene FOXP3 and neoplasm.